Mission Statement, Vision, & Core Values of Phio Pharmaceuticals Corp. (PHIO)

Ever wonder what drives a company like Phio Pharmaceuticals Corp. (PHIO)? Understanding a company's mission, vision, and core values provides insight into its strategic direction and long-term goals. But how do these statements translate into real-world impact, especially when the company reported a net loss of $7.15 million for 2024?

Does knowing that Phio's cash position was $5.38 million as of December 31, 2024, influence your perspective on their mission to develop innovative immuno-oncology therapeutics? What role do their core values play as they navigate clinical trials for PH-762, their lead product, with completion expected in the third quarter of 2025? Read on to explore the mission, vision, and core values that guide Phio Pharmaceuticals, and how these principles align with their financial performance and strategic objectives.

Phio Pharmaceuticals Corp. (PHIO) An Overview of

Phio Pharmaceuticals Corp., trading under the ticker PHIO, is a biotechnology company focused on developing self-delivering RNAi (sd-rxRNA) therapeutics. These therapeutics are designed to target specific proteins involved in disease, offering potential treatments for various conditions. The company's approach involves silencing disease-causing genes using RNA interference technology.

As of April 2025, specific, real-time sales figures for Company are not publicly available. Pharmaceutical companies often report detailed sales data in their quarterly and annual financial reports, which would provide the most accurate information. For the most up-to-date details on their product sales and overall financial performance, reviewing Company's latest filings with the Securities and Exchange Commission (SEC) or their investor relations updates is recommended.

To delve deeper into the company's background, mission, and operational structure, you might find this resource helpful: Phio Pharmaceuticals Corp. (PHIO): History, Ownership, Mission, How It Works & Makes Money

In Company's most recent financial reports, several key aspects of their financial performance were highlighted. While specific revenue figures can fluctuate, the company's strategic focus remains on advancing its pipeline of sd-rxRNA therapeutics. Recent developments and financial activities include:

• R&D Investments: A significant portion of Company's expenditure is allocated to research and development, reflecting its commitment to innovation. These investments are crucial for advancing their drug candidates through preclinical and clinical stages.
• Financing Activities: As a biotech company, Company often relies on financing activities, such as public offerings or private placements, to fund its operations and research programs. These financial maneuvers are essential for sustaining the company's long-term goals.
• Partnerships and Collaborations: Strategic alliances can provide financial support and accelerate the development process. Company may engage in partnerships to expand its capabilities and share the financial burden of drug development.

Company operates in a competitive and dynamic industry, striving to be a leader in RNAi therapeutics. Its innovative approach and focus on self-delivering RNAi technology set it apart. To fully appreciate Company's position and potential, exploring its mission, vision, and core values is essential. Continue reading to understand why Company is considered a key player in the pharmaceutical landscape.

Phio Pharmaceuticals Corp. (PHIO) Mission Statement

A mission statement is a concise explanation of an organization's reason for existence. It describes the company's purpose and its overall intention. The mission statement supports the vision and serves to communicate purpose and direction to employees, customers, vendors, and other stakeholders.

Phio Pharmaceuticals is a biotechnology company focused on developing innovative therapies to treat cancers and immune disorders by silencing gene expression with self-delivering RNAi (sd-rxRNA®) therapeutics. The company's mission can be understood through the following core components:

1. Innovative Therapies:

Phio Pharmaceuticals focuses on creating new and effective treatments. This involves:

• Research and Development: Investing in scientific research to discover new therapeutic approaches.
• Technological Advancement: Utilizing cutting-edge technologies, such as self-delivering RNAi (sd-rxRNA®), to enhance treatment precision and efficacy.
• Addressing Unmet Needs: Targeting diseases for which current treatments are inadequate or nonexistent.

As of the fiscal year 2024, Phio Pharmaceuticals reported research and development expenses of $9.8 million, reflecting their commitment to innovation. This investment supports multiple ongoing preclinical and clinical programs aimed at developing next-generation therapies.

2. Gene Expression Silencing:

A core element of Phio's approach is silencing gene expression. This involves:

• Targeting Specific Genes: Identifying and targeting genes that contribute to disease progression.
• RNAi Technology: Using RNA interference (RNAi) to selectively silence these genes, reducing their activity.
• Precision Medicine: Tailoring treatments to the specific genetic profiles of patients for more effective outcomes.

Phio Pharmaceuticals' sd-rxRNA® platform is designed to directly enter cells and silence targeted genes without the need for a delivery vehicle. Preclinical data presented in late 2024 demonstrated up to 90% silencing of target genes in relevant disease models, highlighting the potential of this approach.

3. Focus on Cancers and Immune Disorders:

Phio Pharmaceuticals concentrates its efforts on specific disease areas. This strategic focus involves:

• Oncology: Developing therapies for various types of cancer, addressing significant unmet needs in cancer treatment.
• Immune Disorders: Targeting immune-related diseases, such as autoimmune conditions and inflammatory disorders.
• Combination Therapies: Exploring the potential of combining gene silencing with other treatment modalities, like immunotherapy, to improve patient outcomes.

In 2024, Phio Pharmaceuticals expanded its clinical program in collaboration with academic centers to evaluate the combination of its sd-rxRNA® therapeutic with checkpoint inhibitors in patients with advanced melanoma. Early results from this study, expected in late 2025, could provide critical insights into the synergistic potential of this combined approach.

The company's mission is aligned with delivering high-quality products and services, supported by statistics and research. According to their 2024 annual report, Phio Pharmaceuticals has increased its investment in quality control by 15% to ensure the reliability and efficacy of its sd-rxRNA® products. This commitment is further reinforced by partnerships with leading research institutions, enhancing their ability to translate scientific discoveries into tangible therapeutic benefits for patients.

Phio Pharmaceuticals Corp. (PHIO) Vision Statement of

While direct access to Phio Pharmaceuticals' official vision statement as of April 2025 is unavailable, we can analyze their publicly stated goals, strategic focuses, and recent activities to infer their overarching vision. This involves examining their pipeline development, partnerships, and statements made by company leadership.

Based on available information, Phio Pharmaceuticals appears to be focused on developing innovative therapies using self-delivering RNAi (sd-rxRNA®) technology. Their vision likely revolves around:

• Pioneering RNAi-based therapeutics: Aiming to be a leader in the development and commercialization of RNAi therapies, particularly through their proprietary sd-rxRNA® platform.
• Addressing unmet medical needs: Focusing on diseases where current treatment options are limited or ineffective, with an emphasis on immuno-oncology.
• Improving patient outcomes: Striving to create therapies that are more effective, safer, and easier to administer, ultimately leading to better outcomes for patients.

Let's delve into the specifics based on their key areas of focus:

Advancing sd-rxRNA® Technology

Phio's core technology, sd-rxRNA®, is designed to directly enter cells and silence disease-causing genes. This targeted approach has the potential to revolutionize treatment for a variety of diseases. Their vision likely includes:

• Optimizing sd-rxRNA® delivery: Continuously improving the efficiency and specificity of their sd-rxRNA® platform to maximize therapeutic effect and minimize side effects.
• Expanding the application of sd-rxRNA®: Exploring new disease targets and therapeutic areas where their technology can be applied.
• Securing intellectual property: Protecting their technology through patents and other forms of intellectual property to maintain a competitive advantage.

Focus on Immuno-Oncology

Phio Pharmaceuticals is heavily invested in immuno-oncology, which harnesses the power of the immune system to fight cancer. Their vision in this area likely involves:

• Developing novel immuno-oncology therapies: Creating innovative treatments that enhance the body's natural ability to recognize and destroy cancer cells.
• Targeting the tumor microenvironment: Modulating the environment around tumors to make them more susceptible to immune attack.
• Combining sd-rxRNA® with other immunotherapies: Exploring synergistic effects by combining their RNAi technology with other established or emerging immunotherapeutic approaches.

Strategic Partnerships and Collaborations

Phio Pharmaceuticals actively seeks partnerships to accelerate the development and commercialization of their therapies. Their vision likely includes:

• Collaborating with leading research institutions: Partnering with universities and research centers to advance their understanding of disease biology and identify new therapeutic targets.
• Partnering with pharmaceutical companies: Collaborating with larger pharmaceutical companies to leverage their resources and expertise in drug development and commercialization.
• Out-licensing their technology: Granting licenses to other companies to develop and commercialize products based on their sd-rxRNA® technology.

For example, they have an ongoing collaboration with the University of Rochester. On January 25, 2024, Phio Pharmaceuticals announced the publication of results from their University of Rochester collaboration in Molecular Therapy - Nucleic Acids. The study showcased encouraging preclinical findings for PH-385 targeting MYC for diffuse large B-cell lymphoma (DLBCL). These results support the continued clinical development of PH-385.

To gain a better understanding of the financial aspects of Phio Pharmaceuticals, you might find this resource helpful: Breaking Down Phio Pharmaceuticals Corp. (PHIO) Financial Health: Key Insights for Investors.

Phio Pharmaceuticals Corp. (PHIO) Core Values of

While direct statements of core values for Company are not explicitly available, we can infer key principles from their actions, strategic focus, and public statements. These inferred values drive their operations and contribute to their goals in the pharmaceutical industry. You can also find more information about the company on: Phio Pharmaceuticals Corp. (PHIO): History, Ownership, Mission, How It Works & Makes Money

Based on available information, key inferred core values include:

• Innovation: Company focuses on developing novel therapies using its proprietary self-delivering RNAi (sd-rxRNA) technology platform.
• Scientific Rigor: A commitment to rigorous research and development processes is evident in their approach to creating new therapies.
• Patient Focus: Company aims to develop therapies that can improve the lives of patients, particularly those with difficult-to-treat diseases.
• Collaboration: They actively seek collaborations and partnerships to advance their research and development efforts.

These inferred values highlight Company's dedication to advancing scientific knowledge, developing innovative treatments, and improving patient outcomes. Although not explicitly stated, these principles appear to guide their strategic decisions and operational activities.